Table 1.
Top five pathways enriched by GeneGO pathway analysis of altered ATP binding proteins on individual cell lines.
| A427 | p Value |
| LRRK2 in neurons in Parkinson‘s disease | 4.62 × 10−11 |
| Development_Slit-Robo signaling | 3.63 × 10−10 |
| Development_Regulation of cytoskeleton proteins | 2.76 × 10−9 |
| Cytoskeleton remodeling_Regulation of actin cytoskeleton by Rho GTPases | 1.53 × 10−8 |
| Regulation of CFTR activity (normal and CF) | 7.02 × 10−8 |
| A549 | p Value |
| LRRK2 in neurons in Parkinson‘s disease | 1.54 × 10−13 |
| Cytoskeleton remodeling_Cytoskeleton remodeling | 2.38 × 10−10 |
| Glycolysis and gluconeogenesis (short map) | 1.29 × 10−9 |
| Cytoskeleton remodeling_Hyaluronic acid/ CD44 signaling pathways | 4.43 × 10−8 |
| Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling | 6.59 × 10−8 |
| Calu-1 | p Value |
| Glycolysis and gluconeogenesis (short map) | 7.76 × 10−7 |
| Regulation of degradation of deltaF508-CFTR in CF | 2.04 × 10−6 |
| Transcription_Role of Akt in hypoxia induced HIF1 activation | 3.03 × 10−6 |
| LRRK2 and immune function in Parkinson's disease | 1.88 × 10−5 |
| Glycolysis and gluconeogenesis p.3 | 2.96 × 10−5 |
| Calu-6 | p Value |
| Cytoskeleton remodeling_Cytoskeleton remodeling | 4.86 × 10−8 |
| CFTR folding and maturation (normal and CF) | 5.09 × 10−8 |
| Cell adhesion_PLAU signaling | 1.11 × 10−7 |
| Development_VEGF signaling via VEGFR2—generic cascades | 5.96 × 10−7 |
| Development_EGFR signaling pathway | 1.3 × 10−6 |
| H157 | p Value |
| LRRK2 in neurons in Parkinson‘s disease | 2.21 × 10−13 |
| Neurophysiological process_Receptor-mediated axon growth repulsion | 6.45 × 10−13 |
| Cytoskeleton remodeling_Cytoskeleton remodeling | 3.35 × 10−11 |
| Development_Slit-Robo signaling | 6.54 × 10−11 |
| Cytoskeleton remodeling_Regulation of actin cytoskeleton by Rho GTPases | 1.14 × 10−10 |